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Abstract
Introduction: Recently, newer assays for cardiac troponin (cTn) have been developed which are able to detect
changes in concentration of the biomarker at or below the 99th percentile for a normal population. The objective
of this study was to compare the diagnostic performance of a new high-sensitivity troponin T (HsTnT) assay to that
of conventional cTnI for the diagnosis of acute myocardial infarction (AMI) according to pretest probability (PTP).
Methods: In consecutive patients who presented to our emergency departments with chest pain suggestive of
AMI, levels of HsTnT were measured at presentation, blinded to the emergency physicians, who were asked to
estimate the empirical PTP of AMI. The discharge diagnosis was adjudicated by two independent experts on the
basis of all available data.
Results: A total of 317 patients were included, comprising 149 (47%) who were considered to have low PTP, 109
(34%) who were considered to have moderate PTP and 59 (19%) who were considered to have high PTP. AMI was
confirmed in 45 patients (14%), 22 (9%) of whom were considered to have low to moderate PTP and 23 (39%) of
whom were considered to have high PTP (P < 0.001). In the low to moderate PTP group, HsTnT levels ≥ 0.014 μg/
L identified AMI with a higher sensitivity than cTnI (91%, 95% confidence interval (95% CI) 79 to 100, vs. 77% (95%
CI 60 to 95); P = 0.001), but the negative predictive value was not different (99% (95% CI 98 to 100) vs. 98% (95%
CI 96 to 100)). There was no difference in area under the receiver operating characteristic (ROC) curve between
HsTnT and cTnI (0.93 (95% CI 0.90 to 0.98) vs. 0.94 (95% CI 0.88 to 0.97), respectively).
Conclusions: In patients with low to moderate PTP of AMI, HsTnT is slightly more useful than cTnI. Our results
confirm that the use of HsTnT has a higher sensitivity than conventional cTnI.
Introduction
Early detection of acute myocardial infarction (AMI)
remains a major concern, with approximately 15 million
patients per year presenting to US emergency departments
(EDs) with symptoms suggestive of the diagnosis [1,2].
Among such patients, a strong association between ele-
vated cardiac troponin (cTn) levels and myocardial necro-
sis has been clearly demonstrated [3-5]. Conventional cTn
has revolutionised the management of patients presenting
with suspected acute coronary syndrome (ACS), including
risk stratification of ACS, and the use of cTn measure-
ments is recommended by current guidelines [6]. A cutoff
point at the 99th percentile has been endorsed, as values
above this level have repeatedly proven to be associated
with adverse cardiovascular outcomes, including death
[7-13]. However, the delay (4 to 6 hours, and 12 hours for
peak level) in its elevation remains of concern, since it can
delay AMI diagnosis and its treatment and increases the
burden on EDs. Thus, cTn measurement does not reliably
exclude AMI without repeated negative measurements
over the course of 4 to 6 hours. These last years, newer
assays have been developed, and High Sensitivity Troponin
(HsTn) has been associated with higher sensitivity and
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excellent diagnostic performance, even with early presen-
tation to the ED [14], and a better diagnostic accuracy
than cTn [15]. However, the latter studies did not evaluate
the diagnostic accuracy of high-sensitivity troponin T
(HsTnT) according to the pretest probability (PTP) of
AMI. For example, ST elevation on an electrocardiogram
of a patient with chest pain would be diagnosed as AMI,
and then the patient would undergo cardiac catheteriza-
tion without any measurement of a cardiac biomarker.
Furthermore, one of the potential strengths of HsTnT
might be the exclusion of AMI earlier than it would be
with conventional cTn measurement as suggested by pre-
vious studies [15]. Therefore, the objectives of the current
s t u d yw e r et oc o n f i r mw h e t h e r HsTnT is more sensitive
than conventional cTnI to detect AMI according to the
patient’sP T P .
Materials and methods
Clinical setting
During the period from August 2005 to January 2007 in
three urban teaching hospitals, we prospectively enrolled
consecutive hospital outpatients (> 18 years of age) who
presented to the ED with chest pain suggestive of ACS
with the onset or peak occurring within the previous 6
hours. Patients with acute or chronic kidney failure requir-
ing dialysis were excluded. The study was performed
according to the principles of the Declaration of Helsinki
and approved by the local ethics committee (Comité de
Protection des Personnes Ile-de-France VI, CHU Pitié-
Salpétrière Hospital, Paris, France). Because routine medi-
cal care was unchanged, waiver of informed consent was
authorised. We followed most of the recommendations
concerning the reporting of diagnostic studies set forth by
the Standards for Reporting of Diagnostic Accuracy initia-
tive [16].
Routine assessment
As part of the routine assessment in our institutions, all
patients underwent an initial clinical evaluation that
included clinical history, a physical examination, 12-lead
electrocardiography (ECG),p u l s eo x i m e t r y ,r o u t i n e
blood tests and chest X-rays. After these routine tests
were done, and before cardiac biomarker results were
available, ED physicians were asked to offer an ‘empiri-
cal’ clinical probability of AMI (low, medium or high
PTP) based on cardiovascular risk factors, type of chest
pain, physical findings and electrocardiogram abnormal-
ities [17,18]. Conventional cardiac troponin I (cTnI) was
measured at presentation and, if needed, was repeated
after 3 to 9 hours as long as it was clinically indicated.
Thus, according to the diagnosis of non-ST elevation
MI (NSTEMI) or ST elevation MI (STEMI), the patients
were admitted either to the cardiology unit for further
evaluation and treatment or directly to the catheteriza-
tion laboratory for primary percutaneous coronary inter-
vention. However, the timing and treatment of patients
were left to the discretion of the attending physicians
according to the suspected diagnosis. ED physicians in
charge were blinded to the results of HsTnT, and biolo-
gists were blinded to the emergency diagnosis suspected
by physicians.
To determine the etiologic diagnosis of chest pain at
presentation for each patient, two independent experts
(ED physicians) who were blinded to the results of HsTnT
reviewed all available medical records (including patient
history, physical findings, results of laboratory and radiolo-
gic testing, ECG, echocardiography, cardiac exercise test,
coronary angiography and summary chart at discharge)
pertaining to the patient from the time of ED presentation
to 30-day follow-up. In the event of diagnostic disagree-
ment, cases were reviewed and adjudicated in conjunction
with a third expert (also an ED physician).
AMI was diagnosed according to the joint European
Society of Cardiology/American College of Cardiology/
American Heart Association/World Heart Federation
Task Force redefinition of MI guidelines [6]. Diagnosis of
AMI required a cTnI increase above the 10% coefficient of
variation (CV) value associated with at least one of the fol-
lowing: symptoms of ischaemia, new ST-T changes or a
new Q wave on an electrocardiogram, imaging of new loss
of viable myocardium or normal cTnI on admission.
Unstable angina was diagnosed in patients with constant
normal cTnI levels and a history or clinical symptoms
consistent with ACS. Predefined further diagnostic cate-
gories included AMI (STEMI with the presence of ST-
segment elevation in at least two continuous leads on
ECG, new onset of left bundle branch block or NSTEMI),
unstable angina, and a third group including cardiac but
not coronary symptoms (for example, stable angina, myo-
carditis, arrhythmias and heart failure), noncardiac symp-
toms (for example, pulmonary embolism) and chest pain
of unknown origin.
To assess the influence of renal function on cTn mea-
surement accuracy, the creatinine level was measured in
each patient and then renal function was estimated
using the Modification of Diet in Renal Disease study
equation [19].
Biochemical analysis
In two EDs (Cochin Hospital and La Pitié Salpêtrière Hos-
pital, Paris, France), plasmatic cTnI concentrations were
routinely measured on an Xpand HM analyzer using the
Cardiac Troponin I one-step enzyme immunoassay system
(Siemens Healthcare Diagnostics Inc., Newark, NJ, USA).
The measurement range extended from 0.04 to 40.00 μg/L.
The threshold for this method (0.14 μg/L) corresponds to
the lowest substrate concentration that can be reproducibly
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Hospital, Le Kremlin-Bicêtre, France), plasmatic cTnI con-
centrations were routinely measured on an Access analyser
(Beckman Coulter, Inc., Brea, CA, USA). The measurement
range of this one-step chemiluminescence immunoassay
extends from 0.01 to 100.00 μg/L. The threshold (10% CV)
given by the manufacturer is 0.06 μg/L.
HScTnT measurement
Heparinised samples collected upon admission and, if
available, samples collected 3 to 9 hours later were ana-
lysed. Plasmatic highly sensitive cardiac TnT (HScTnT)
concentrations were measured using the HScTnT one-
step electrochemiluminescence immunoassay on an
Elecsys 2010 analyzer (Roche Diagnostics, Meylan,
France). The measuring range extended from 0.003 to
10 μg/L. The threshold for this method is 0.014 μg/L and
corresponds to the 99th percentile. The CV was found to
be < 10% at 0.014 μg/L. In our laboratory, CVs obtained
in Roche Diagnostics quality controls containing 0.027
and 2.360 μg/L of HScTnT were < 4%. These analytical
p e r f o r m a n c el e v e l sw e r ei na c c o r d a n c ew i t hd a t ap r o -
vided by the manufacturer.
Statistical analysis
Continuous variables are presented as means ± SD or
medians (25th to 75th percentile), and categorical variables
are expressed as numbers and percentages. Continuous
variables were compared by using the Mann-Whitney U
test, and categorical variables were assessed using Pear-
son’s c
2 test. Correlations among continuous variables
were assessed using the Spearman’s rank correlation coef-
ficient. Receiver operating characteristic (ROC) curves
were constructed to assess the sensitivity and specificity,
positive predictive value (PPV) and negative predictive
value (NPV), positive likelihood ratio (LR
+)a n dn e g a t i v e
likelihood ratio (LR
-) (all data presented with their 95%
confidence intervals (95% CIs)) throughout the concentra-
tions of cTnI and HScTnT to compare the accuracy of
these markers in the diagnosis of AMI. Comparison of
areas under the ROC curve was performed [20]. As this
comparison is recognised as potentially insensitive, the net
reclassification index (NRI) method was used as recently
described [21]. For tests with binary outcomes (such as
cTn for the diagnosis of AMI), NRI is defined as the gain
in certainty of the first test (cTnI) minus the gain in cer-
tainty of the second test (HScTnT) or, alternatively stated,
the difference of the sum of the sensitivity and specificity
expressed as follows:
NRIHScTnT vs. cTnI = (sensitivity + speciﬁcity)HScTnT − (sensitivity + speciﬁcity)cTnI.
NRI is the combination of four components: the pro-
portion of individuals with events who move up or
down in a category and the proportion of individuals
with nonevents who move up or down in a category.
Table 1 is a contingency table comparing diagnostic
classifications according to cTnI and HsTnT, with shifts
between the two classifications, to represent the possible
benefit of HScTnT in terms of the number of patients
correctly reclassified. As stated in the Routine assess-
ment subsection above, we separated the study popula-
tion into two groups: one included the patients assessed
as having low or moderate PTP of AMI and the other
assessed as having high PTP of AMI.
All hypothesis testing was two-tailed, and P < 0.05 was
considered statistically significant. Statistical analysis was
performed using StatView for Windows version 5.0 soft-
ware (SAS Institute, Cary, NC, USA) and MedCalc soft-
ware for ROC analysis (MedCalc Software, Mariarkerke,
Belgium). Graphs were built with GraphPad Prism 5
software (GraphPad Software Inc., La Jolla, CA, USA).
Results
After 18 months, 317 consecutive patients were enrolled
in the study. The baseline characteristics of the patients
are shown in Table 2. The mean age of the patients was
57 ± 17 years (range, 40 to 90 years), and 205 (65%)
were men. There were significant proportions of older
adult patients (31% patients were age 65 years or older,
n = 98) and patients with a history of cardiovascular
events (26%, n = 83). Chest pain was considered typical
of ACS in 43% (n = 136) of the patients. In our study
Table 1 Contingency data according to pretest
probability
a
All patients
Patient characteristics AMI No AMI Total
Positive cTnI 32 9 41
Negative cTnI 13 263 276
Total 45 272 317
Positive HsTnT 42 48 90
Negative HsTnT 3 224 227
Total 45 272 317
Low to moderate PTP
AMI No AMI Total
Positive cTnI 17 7 24
Negative cTnI 5 229 234
Total 22 236 258
Positive HsTnT 20 36 56
Negative HsTnT 2 200 202
Total 22 236 258
aNet reclassification improvement (NRI) from the use of highly sensitive
troponin T (HsTnT) was 7.9% (95% CI = 0.9 to 14.9; P = 0.034). Comparison of
the model including HsTnT with cTnI was significant for low PTP patients
(NRI = 10.3%, 95% CI = 1.9 to 18.7; P = 0.027), but NRI was not significantly
different in moderate PTP patients (NRI = 11.6%, 95% CI = -0.5 to 23.7; P =
0.084) or in high PTP patients (NRI = -14.4%, 95% CI = -32.6 to -3.6; P = 0.181).
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low PTP of AMI, 109 patients (34%) were assessed as
moderate and 59 patients (19%) were assessed as high.
AMI was confirmed in 45 patients (14%), 13 of whom
had sustained STEMI, and all of these 13 patients were
in the high PTP group; 32 of the patients had sustained
NSTEMI. Table 2 shows that patients in the two groups
(high PTP and low or moderate PTP) had significantly
different characteristics. There was a higher rate of a
personal history of AMI in the high PTP group and a
higher final diagnosis of AMI (39% vs. 9%) in the high
PTP group (P < 0.001). At 30 days after admission,
there were three deaths (two in the AMI group and one
in the other cause group) and four relapses of ACS (all
in the AMI group).
HsTnT diagnostic performances
The area under the ROC curve (AUC) for the diagnosis
of AMI was 0.940 (95% Confidence Intervall 0.901 to
0.980) (P < 0.001) for initial cTnI compared to 0.926
Table 2 Baseline characteristics of the population according to the pretest probability
a
Population characteristics All patients Low or moderate PTP High PTP P value*
Number of patients 317 258 59
Age, years 57 ± 17 56 ± 17 60 ± 17 0.168
Men 205 (65) 166 (64) 39 (66) 0.88
Systolic BP, mmHg 141 ± 28 141 ± 27 144 ± 30 0.396
Diastolic BP, mmHg 80 ± 16 80 ± 16 82 ± 16 0.428
Heart rate, beats/minute 85 ± 45 84 ± 23 80 ± 19 0.177
Pulse oxymetry, % 97 ± 3 97 ± 3 97 ± 2 0.651
TIMI risk score 1 (0 to 3) 1 (0 to 2) 2 (1 to 4) < 0.001
Family history of CAD 100 (32) 77 (30) 23 (59) 0.161
Personal history of CAD 83 (26) 56 (22) 27 (46) 0.0003
Dyslipidemia 113 (36) 86 (33) 27 (46) 0.069
Smoking 128 (40) 99 (38) 29 (49) 0.145
Diabetes 44 (14) 31 (12) 13 (22) 0.059
Hypertension 116 (37) 89 (34) 27 (46) 0.134
History of heart failure 21 (7) 14 (5) 7 (12) 0.083
Typical thoracic pain 136 (43) 105 (41) 31 (53) 0.11
Positive cTnI at admission 41 (13) 24 (9) 17 (29) < 0.001**
eGFR, mL/minute/1.73 m
2 77 (62 to 94) 77 (64 to 94) 76 (56 to 91) 0.187
Treatment within first 24 hours after admission
Aspirin 119 (38) 79 (31) 40 (68) <0.001
Clopidogrel 54 (17) 29 (11) 25 (42) < 0.001
LMWH 68 (21) 41 (16) 27 (46) < 0.001
Anti GPIIb/IIIa 3 (1) 1 (0) 2 (3) 0.09
Coronarography 83 (26) 51 (20) 32 (54) < 0.001
Outcomes
Hospital admission 192 (61) 140 (54) 52 (88) < 0.001
Admission to CCU 134 (42) 88 (34) 46 (78) < 0.001
Final diagnosis
AMI 45 (14) 22 (9) 23 (39) < 0.001
STEMI 13 (4) 0 (0) 13 (22) < 0.001
NSTEMI 32 (10) 22 (9) 10 (17) < 0.001
Unstable angina 11 (3) 4 (2) 7 (12) < 0.001
Other diagnosis 261 (82) 232 (90) 29 (49) < 0.001***
aAMI, acute myocardial infarction; BP, blood pressure; CAD, coronary artery disease; cTnI, conventional troponin I; eGFR, estimated glomerular filtration rate;
LMWH, low-molecular-weight heparin; anti-GPIIb/IIIa, Anti-glycoprotein IIb-IIIa; CCU, cardiologic care unit; NSTEMI, non-ST elevation myocardial infarction; PTP,
pretest probability; STEMI, ST elevated myocardial infarction. TIMI, Thrombolysis in Myocardial Infarction. Results are expressed as means ± standard deviations,
medians (25th to 75th percentile) or n (%); *statistical comparisons are between low to moderate PTP and high PTP groups unless otherwise indicated; **P > 0.14
μg/L in Pitie-Salpetriere and Cochin, P > 0.06 μg/L in Bicêtre; ***Statistical comparison including stable angina (n = 63), pulmonary embolism (n = 16),
myopericarditis (n = 43), heart failure (n = 5) and others.
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Page 4 of 9(0.881 to 0.971) (P < 0.001) for HsTnT. However, there
was no significant difference between AUCs (Figure 1).
ROC analysis indicated an optimal threshold of HsTnT
for the diagnosis of AMI at 0.014 μg/L, with a high sen-
sitivity of 89% (78 to 98) and a high specificity of 82%
(78 to 87). The overall diagnostic accuracy of HsTnT
was not significantly different compared to that of cTnI,
regardless of PTP. Similar results (data not shown) were
observed when we considered only NSTEMI patients
(that is, after exclusion of the 13 STEMI patients). For
the diagnosis of AMI, the sensitivities of HsTnT were
higher and the specificities were lower than those of
cTnI, regardless of PTP (Table 3). When we assessed
the low and moderate PTP populations, the sensitivity
of HsTnT was higher (91% (79 to 100) vs. 77% (60 to
95)) but NPV was not (99% (96 to 100) vs. 98% (95 to
99) for cTnI).
Net reclassification improvement
Table 3 shows patient classification on the basis of using
cTnI or HsTnT to diagnose AMI and highlights the
shifts between the two classifications.
Influence of renal function on cTn performances
Patients were classified into tertiles: tertile 1 (estimated
glomerular filtration rate (eGFR) < 67.2 ml
-1 minute
-1
1.73 m
-2), tertile 2 (eGFR from 67.2 to 86.8 ml
-1 min-
ute
-1 1.73 m
-2) and tertile 3 (eGFR ≥ 86.9 ml
-1 minute
-1
1.73 m
-2). Cardiac TnI levels were not significantly dif-
ferent across tertiles. However, HsTnT increased signifi-
cantly across tertiles (P < 0.001): the lower the eGFR,
the higher the HsTnT value. However, in each eGFR
tertile, cTnI and HsTnT levels remained significantly
Figure 1 ROC curves for the diagnosis of AMI. Values were log-
transformed before analysis. AUC: area under the curve; cTnI:
conventional troponin I; HSTnT: highly sensitive troponin T.
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both) (Figure 2). We found no significant differences in
the AUCs of cTnI and HsTnT regarding eGFR tertiles,
and the optimal threshold value of cTnI did not change
across tertiles. Conversely, the optimal threshold value
of HsTnT increased only in tertile 1 (0.036 μg/L com-
pared to 0.014 μg/L).
Discussion
During the past two decades, cTn has been adopted as
the preferred biomarker for the diagnosis of acute MI, a
position reaffirmed in recent consensus guidelines
[14,22]. However, until recently, cTn methods were
unable to deliver the requisite analytic performance at
the 99th percentile, an extremely low cutoff point within
the range of analytic ‘noise’ in most conventional assays.
The present prospective multicenter study of unselected
patients who presented to the ED with chest pain of < 6
hours’ duration produced major different findings about
the new HsTnT assay.
First, the sensitivity of the HsTnT assay remains high
at all PTP levels. The excellent sensitivity of 93% was
comparable to that found in a previous study (84% to
90% [22]) and significantly higher than conventional
cTn (69% in our study and 72% previously described
[14]). However, despite its good sensitivity of 91% in the
low and moderate PTP groups, the use of HsTnT assays
would not allow physicians to rule out AMI in these
patients with a unique measurement of HsTnT, as the
NPV is not quite perfect, that is, a unique value < 0.014
μg/L cannot avoid a second blood test several hours
later to control HsTnT level. It should be noted that in
the high PTP group, HsTnT showed excellent diagnostic
accuracy, with 93% sensitivity (compared to 80% for
cTnI) and 96% NPV (compared to 93% for cTnI).
Recently, Januzzi et al. [15] showed that HsTnT was
able to detect ACS more sensitively than a correspond-
ing conventional cTnT method in a population of low
to moderate PTP patients with chest pain.
Second, we confirmed the value of 0.014 μg/L as an
optimal threshold [14,22]. We confirmed the high diag-
nostic accuracy of HsTnT; the AUC of HsTnT was 0.93,
similar to that found by investigators in previous studies.
Thus, Keller et al. [22] and Reichlin et al. [14] found
AUCs that ranged from 0.94 to 0.96. However, and con-
versely to other reports, our findings do not show a better
AUC for HsTnT than for conventional cTnI measure-
ments. Several reasons could explain this discrepancy.
First, we used cTnI (from Siemens and Beckman
Coulter) instead of cTnT as the comparator, thus with a
different assay than was previously used, and our com-
parator cTnI could have slightly better analytical quali-
ties than the one called the ‘standard assay’ that was
used in the Reichlin et al. study [14]. Second, in our
study, the AUC for cTnI, or ‘conventional troponin’,
that is, the comparator, was 0.94 (95% CI, 0.90 to 0.98),
which in fact is included in the 95% CIs of the AUCs of
other comparators previously used. For example, Christ
et al. [23] found an AUC of the standard fourth-genera-
tion cTnT assay, that is, its comparator, of 0.89 (95% CI,
0.81 to 0.98). Unfortunately, Keller et al. [22] did not
detail the 95% CIs of their AUCs for cTn, and Reichlin
et al. [14] used an old standard assay which in fact
underestimated the diagnostic performance of the cTn
assay. Other reasons could explain this discrepancy in
the AUC of ROC curves for cTnI. Our inclusion criteria
differ from those of Reichlin et al. [14], Keller et al. [22]
and others who included patients with chest pain of less
than 12 hours’ duration with high rates of AMI and
unstable angina. Our population markedly differs from
those in previous studies. Thus, other conventional
cTnT assays (also called third-generation cTnTs, from
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Page 6 of 9Roche Diagnostics) that could be used in studies as
comparators for HSTnT have been reported to have
excellent AUCs. Collinson et al. [24] found that at 6
hours postpain, the AUC of cTnT was 0.989 (95% CI,
0.966 to 1.0). However, although the comparison of
AUCs remains the most popular metric by which to
capture discrimination, it appears that for models con-
taining clinical risk and possessing reasonably good dis-
crimination, very important associations between the
biomarker and the end point are required to provide
significantly different AUCs. In other words, compari-
sons of AUCs might be considered powerless in identi-
fying biomarkers of interest in such situations [20]. To
address this problem, new ways of evaluating the useful-
ness of biomarkers have been described, but they are
used very rarely in studies evaluating diagnostic tests or
biomarkers [14,22]. In the present study, reclassification,
for example, NRI, demonstrated that the use of HsTnT
with a clinical assessment (including ECG findings) only
slightly improved the discriminative power and perfor-
mance in predicting AMI [14,22,25]. As described in
previous studies, we have demonstrated a worsening of
specificity and lower PPV of HsTnT measurement com-
pared to those of conventional cTn; that is, we observed
an increase in false-positive findings. Last, the present
study is the first to investigate the impact of kidney
function on HsTnT levels. We found no significant dif-
ference in the AUCs of HsTnT regarding eGFR tertiles.
Only in tertile 1 was the optimal threshold value of
HsTnT increased (0.036 μg/ml compared to 0.014 μg/L).
Conventional cTn is widely used and is recommended
for the management of patients presenting with sus-
pected ACS [6]. However, the delay in detecting its ele-
vation prevents early, safe discharge from the ED
without repeated negative measurements during the
course of 4 to 6 hours. Recent studies have shown excel-
lent diagnostic performance of HsTnT measurement,
even with early presentation to the ED [14], and better
diagnostic accuracy than cTn [15]. Despite its higher
sensitivity, we did not find that HsTnT had better NPV,
diagnostic accuracy or AUC, conversely to the findings
of previous studies [15]. Furthermore, as expected, spe-
cificity and PPV were lower. The clinical setting, time of
inclusion, rate of AMI in our patient population and
our focus on low or moderate PTP of AMI could
explain this discrepancy.
The emergency medicine field would greatly benefit from
a new biomarker that eases and hastens the triage of non-
cardiac chest pain patients. The main incremental value
that could have provided a new highly sensitive assay for
Tn would have allowed emergency physicians to rule out
AMI and discharge patients with a normal Tn value. This
study suggests that even when considering only low to
moderate PTP patients, the better sensitivity of HsTnT
cannot translate into a real clinical improvement. A NPV
of 99% can be interpreted as excellent, but this slight gain
from that of cTnI is not sufficient to change the conven-
tional method of chest pain investigation in our ED, even
in low to moderate PTP patients. This subgroup is the one
of most interest in our study, as high PTP patients (and
even more so for STEMI patients) are not to be promptly
discharged and will more easily undergo further investiga-
tions and care.
To rapidly and reliably rule out AMI, the answer may
be assessment of a combination of different biomarkers,
as suggested by Reichlin et al. [26] in their study, where
they found that with a copeptin level < 14 pmol/L and a
TnT level < 0.01 μg/L, AMI was excluded with 99.7%
NPV in an unselected population of chest pain patients.
Limitations
The main limitation of our study is the small sample of
patients, especially patients with AMI. We cannot
exclude the possibility that better results might have
been found with a larger sample. Our sample is compar-
able to those used in previous studies, however, and
most of all, we believe that the imperfect NPV that we
describe herein is the major result of our study, which
could not have been corrected by including more
patients.
Our study has some other limitations. First, we per-
formed only a single measurement of HsTnT. We did not
evaluate its kinetics, which would have been interesting,
especially in the ‘grey zone’ (between 0.014 μg/L and 0.050
μg/L). A second value could have provided more data, as
previously described in the Giannitsis et al. study [27],
which reported that a doubling in the HsTnT concentra-
tion within 3 hours of chest pain (with first negative
HsTnT and no electrocardiogram abnormality) was asso-
ciated with a 100% PPV of a diagnosis of NSTEMI.
Second, we used empirical PTP and not a standardised,
validated one [17,18]. However, outcomes in the low and
moderate PTP population (only nine with confirmed
NSTEMI), and differences in clinical characteristics at
admission suggested that even though empirical, this eva-
luation by the clinician was accurate. Furthermore, one of
the strengths of our study was that it evaluated differ-
ences in diagnostic performance for the HsTnT regarding
PTP as demonstrated for D-dimers and empirical suspi-
cion of pulmonary embolism [28]. Another limitation of
our study is that different conventional Tn assays have
been used at the two study sites with different threshold
values and CVs. These assays were used because they
were both local and well-understood methods at the time
of the study.
Third, we used two different assays for the comparator
(that is, conventional TnI): a Siemens cTnI assay in two
centres (CCH and PSL) and a Beckman Coulter assay in
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Page 7 of 9the third centre (BCT). The ROC curve for the cTnI is,
then, a combined ROC curve of two different assays,
making it imprecise. However, the two different ROC
curves (for each assay) have similar AUCs.
Last, this study was underpowered to find any signifi-
cant change in the detection of AMI in the low to mod-
erate PTP patients. However, as the NPV is not perfect
in our patient population,w ee x p e c tt h a tt h i sw o u l d
remain the case with a larger sample.
Conclusions
We have confirmed that HsTnT is accurate for diagno-
sis of AMI, with a sensitivity slightly higher than that of
conventional cTnI, regardless of PTP of AMI in patients
with chest pain presenting to an ED. However, we did
not show a better NPV. Intervention studies are clearly
warranted to support the use of HsTnT to help ED phy-
sicians achieve clinical improvement in treating patients
with chest pain and providing them with an early, safe
discharge from the hospital.
Key messages
￿ Fast and reliable detection of ACS remains a great
concern in the ED.
￿ Novel assays for troponin have been developed and
tested recently.
￿ HsTnT is more sensitive than cTn.
￿ In this study, the weak gains realised by measuring
HsTnT rather than cTn in terms of NPV is not suffi-
cient to change daily clinical practice.
Abbreviations
ACS: acute coronary syndrome; AMI: acute myocardial infarction; AUC: area
under the curve; cTn: conventional troponin; CV: coefficient of variation; ED:
emergency department; HsTn: high-sensitivity troponin; LR: likelihood ratio;
NPV: negative predictive value; NRI: net reclassification improvement;
NSTEMI: non-ST elevation myocardial infarction; PPV: positive predictive
value; PTP: pretest probability; ROC: receiver operating characteristic; SD:
standard deviation; STEMI: ST elevation myocardial infarction.
Acknowledgements
We thank Roche Diagnostics France (Meylan, France) for providing free
reagents and kits for HsTnT assays. The tests and kits for the HsTnT assays
were provided free of charge by Roche Diagnostics France. Other sources of
support were provided solely from departmental sources.
We also thank Dr DJ Baker (Department of Anaesthesiology, CHU Necker-
Enfants Malades, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris,
France) for reviewing the manuscript. This study was partially presented at
the research forum of the 2010 scientific assembly of the American College
of Emergency Physicians, Las Vegas, NV, USA, 29 September 2010.
Author details
1Department of Emergency Medicine and Surgery, Hôpital Pitié-Salpétrière,
Assistance Publique-Hôpitaux de Paris (APHP), Université Pierre et Marie
Curie-Paris 6 (UPMC), 47-83 boulevard de l’hôpital, F-75651 Paris cedex 13,
France.
2Department of Biochemistry, Hôpital Cochin-Hôtel Dieu, APHP, 27
rue du Faubourg Saint-Jacques, F-75679 Paris cedex 14, France.
3Department
of Emergency Medicine, Hôpital Cochin-Hôtel Dieu, APHP, Université Paris
Descartes-Paris 5, 27 rue du Faubourg Saint-Jacques, F-75679 Paris cedex 14,
France.
4Department of Emergency, Hôpital Bichat, APHP, 46 rue Henri
Huchard, F-75018, Paris, France.
5Department of Biochemistry, Hôpital Bicêtre,
APHP, 78 rue du Général Leclerc 94270, Le Kremlin-Bicêtre, France.
6INSERM
UMRS 956, UPMC, 91 Boulevard de l’Hôpital, F-75013 Paris, France.
Authors’ contributions
CCG, BR and PR designed the study. PB, YEC, JCA, BD, FL and CC helped in
collecting the data. CC and YF carried out the statistical analyses and the
biochemical assays. YF, CCG, BR and PR wrote the paper. All authors read
and approved the final manuscript.
Competing interests
CCG, PR and BR received honoraria from Thermo Fisher Scientific B.R.A.H.M.S.
(Hennigsdorf, Germany). PR received an honorarium from bioMérieux, Roche
Diagnostics France (Lyon, France).
Received: 1 February 2011 Revised: 19 April 2011
Accepted: 10 June 2011 Published: 10 June 2011
References
1. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation
Acute Coronary Syndromes of European Society of Cardiology, Bassand JP,
Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA,
Hasdai D, Ohman EM, Wallentin L, Wijns W: Guidelines for the diagnosis
and treatment of non-ST-segment elevation acute coronary syndromes.
Eur Heart J 2007, 28:1598-1660.
2. Nawar EW, Niska RW, Xu J: National Hospital Ambulatory Medical Care
Survey: 2005 emergency department summary. Adv Data 2007, 386:1-32.
3. Hamm CW, Ravkilde J, Gerhardt W, Jørgensen P, Peheim E, Ljungdahl L,
Goldmann B, Katus HA: The prognostic value of serum troponin T in
unstable angina. N Engl J Med 1992, 327:146-150.
4. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, for the FRISC Study
Group: Markers of myocardial damage and inflammation in relation to
long-term mortality in unstable coronary artery disease. N Engl J Med
2000, 343:1139-1147.
5. Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH,
Cannon CP, Fischer GA, Fung AY, Thompson C, Wybenga D, Braunwald E:
Cardiac-specific troponin I levels to predict the risk of mortality in
patients with acute coronary syndromes. N Engl J Med 1996,
335:1342-1349.
6. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for
the Redefinition of Myocardial Infarction: Universal definition of
myocardial infarction. J Am Coll Cardiol 2007, 50:2173-2195.
7. Eggers KM, Jaffe AS, Lind L, Venge P, Lindahl B: Value of cardiac troponin I
cutoff concentrations below the 99th percentile for clinical decision-
making. Clin Chem 2009, 55:85-92.
8. Apple FS, Pearce LA, Smith SW, Kaczmarek JM, Murakami MM: Role of
monitoring changes in sensitive cardiac troponin I assay results for early
diagnosis of myocardial infarction and prediction of risk of adverse
events. Clin Chem 2009, 55:930-937.
9. Apple FS, Smith SW, Pearce LA, Ler R, Murakami MM: Use of the Centaur
TnI-Ultra assay for detection of myocardial infarction and adverse events
in patients presenting with symptoms suggestive of acute coronary
syndrome. Clin Chem 2008, 54:723-728.
10. Eggers KM, Lagerqvist B, Venge P, Wallentin L, Lindahl B: Persistent cardiac
troponin I elevation in stabilized patients after an episode of acute
coronary syndrome predicts long-term mortality. Circulation 2007,
116:1907-1914.
11. James SK, Lindahl B, Armstrong P, Califf R, Simoons ML, Venge P,
Wallentin L: A rapid troponin I assay is not optimal for determination of
troponin status and prediction of subsequent cardiac events at
suspicion of unstable coronary syndromes. Int J Cardiol 2004, 93:113-120.
12. Venge P, Lagerqvist B, Diderholm E, Lindahl B, Wallentin L: Clinical
performance of three cardiac troponin assays in patients with unstable
coronary artery disease (a FRISC II substudy). Am J Cardiol 2002,
89:1035-1041.
13. Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH,
Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS,
Braunwald E: Ability of minor elevations of troponins I and T to predict
benefit from an early invasive strategy in patients with unstable angina
and non-ST elevation myocardial infarction: results from a randomized
trial. JAMA 2001, 286:2405-2412.
Freund et al. Critical Care 2011, 15:R147
http://ccforum.com/content/15/3/R147
Page 8 of 914. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S,
Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T,
Twerenbold R, Winkler K, Bingisser R, Mueller C: Early diagnosis of
myocardial infarction with sensitive cardiac troponin assays. N Engl J
Med 2009, 361:858-867.
15. Januzzi JL Jr, Bamberg F, Lee H, Truong QA, Nichols JH, Karakas M,
Mohammed AA, Schlett CL, Nagurney JT, Hoffmann U, Koenig W: High-
sensitivity troponin T concentrations in acute chest pain patients
evaluated with cardiac computed tomography. Circulation 2010,
121:1227-1234.
16. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM,
Moher D, Rennie D, de Vet HC, Lijmer JG, Standards for Reporting of
Diagnostic Accuracy: The STARD statement for reporting studies of
diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003,
138:W1-W12.
17. Chandra A, Lindsell CJ, Limkakeng A, Diercks DB, Hoekstra JW, Hollander JE,
Kirk JD, Peacock WF, Gibler WB, Pollack CV, EMCREG i*trACS Investigators:
Emergency physician high pretest probability for acute coronary
syndrome correlates with adverse cardiovascular outcomes. Acad Emerg
Med 2009, 16:740-748.
18. Pollack CV Jr, Braunwald E: 2007 update to the ACC/AHA guidelines for
the management of patients with unstable angina and non-ST-segment
elevation myocardial infarction: implications for emergency department
practice. Ann Emerg Med 2008, 51:591-606.
19. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate
method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 1999, 130:461-470.
20. Ray P, Le Manach Y, Riou B, Houle TT: Statistical evaluation of a
biomarker. Anesthesiology 2010, 112:1023-1040.
21. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS: Evaluating the
added predictive ability of a new marker: from area under the ROC
curve to reclassification and beyond. Stat Med 2008, 27:157-172,
discussion 207-112.
22. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, Bickel C, Baldus S,
Warnholtz A, Fröhlich M, Sinning CR, Eleftheriadis MS, Wild PS, Schnabel RB,
Lubos E, Jachmann N, Genth-Zotz S, Post F, Nicaud V, Tiret L, Lackner KJ,
Münzel TF, Blankenberg S: Sensitive troponin I assay in early diagnosis of
acute myocardial infarction. N Engl J Med 2009, 361:868-877.
23. Christ M, Popp S, Pohlmann H, Poravas M, Umarov D, Bach R, Bertsch T:
Implementation of high sensitivity cardiac troponin T measurement in
the emergency department. Am J Med 2010, 123:1134-1142.
24. Collinson PO, Gaze DC, Morris F, Morris B, Price A, Goodacre S: Comparison
of biomarker strategies for rapid rule out of myocardial infarction in the
emergency department using ACC/ESC diagnostic criteria. Ann Clin
Biochem 2006, 43:273-280.
25. Levinson SS: Clinical validation of biomarkers for predicting risk. Adv Clin
Chem 2009, 48:1-25.
26. Reichlin T, Hochholzer W, Stelzig C, Laule K, Freidank H, Morgenthaler NG,
Bergmann A, Potocki M, Noveanu M, Breidthardt T, Christ A, Boldanova T,
Merki R, Schaub N, Bingisser R, Christ M, Mueller C: Incremental value of
copeptin for rapid rule out of acute myocardial infarction. J Am Coll
Cardiol 2009, 54:60-68.
27. Giannitsis E, Becker M, Kurz K, Hess G, Zdunek D, Katus HA: High-sensitivity
cardiac troponin T for early prediction of evolving non-ST-segment
elevation myocardial infarction in patients with suspected acute
coronary syndrome and negative troponin results on admission. Clin
Chem 2010, 56:642-650.
28. Carrier M, Righini M, Djurabi RK, Huisman MV, Perrier A, Wells PS, Rodger M,
Wuillemin WA, Le Gal G: VIDAS D-dimer in combination with clinical pre-
test probability to rule out pulmonary embolism: a systematic review of
management outcome studies. Thromb Haemost 2009, 101:886-892.
doi:10.1186/cc10270
Cite this article as: Freund et al.: High-sensitivity versus conventional
troponin in the emergency department for the diagnosis of acute
myocardial infarction. Critical Care 2011 15:R147.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Freund et al. Critical Care 2011, 15:R147
http://ccforum.com/content/15/3/R147
Page 9 of 9